Setting the TEMPO: What have we learned about D1/D5 dopamine stimulation in Parkinson’s disease?

Dr. Divyani Garg speaks with Dr. Hubert H. Fernandez about tavapadon, a once-daily selective dopamine D1/D5 receptor agonist, and what the TEMPO clinical development program tells us about its potential role in Parkinson’s disease (PD). They discuss the rationale for D1/D5 stimulation, findings from other TEMPO programs, the magnitude and clinical meaning of the motor benefit, flexible dosing, and the important tolerability and discontinuation findings from TEMPO-2. The conversation also explores where tavapadon might fit relative to levodopa and conventional D2/D3 dopamine agonists, and its potential role across different stages of PD. Read the article.